Bristol-Myers Squibb Co.

-1.05 (-1.63%)

Bristol Myers Squibb's Applications For Plaque Psoriasis Treatment Accepted By FDA And Validated By EMA

Published: 11/29/2021 12:30 GMT
Bristol-Myers Squibb Co. (BMY) - Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency.
Bristol-myers Squibb Co - U.S. Food and Drug Administration Assigned a Target Action Date of September 10, 2022.
Bristol-myers Squibb Co - European Medicines Agency Validation Confirms Submission is Complete and Begins Centralized Review Process.